首页|P-gp、GSTπ联合TOPOⅡα检测对三阴性乳腺癌新辅助化疗病理完全缓解的预测价值

P-gp、GSTπ联合TOPOⅡα检测对三阴性乳腺癌新辅助化疗病理完全缓解的预测价值

扫码查看
目的 分析P-糖蛋白(P-gp)、谷胱甘肽转移酶(GSTπ)联合拓扑异构酶Ⅱα(TOPOⅡα)检测对三阴性乳腺癌(TNBC)患者新辅助化疗(NAC)病理完全缓解(pCR)的预测价值.方法 本研究为一项回顾性、单中心、双盲法的试验,选取郑州大学第一附属医院自2020年3月至2022年10月,经纳入、排除标准共筛查135名TNBC患者作为研究对象,均为女性.采用SP免疫组化法检测P-gp、GSTπ、TOPOⅡα,分析TNBC患者NAC疗效,行单因素、多因素分析P-gp、GSTπ、TOPOⅡα表达与NAC pCR的关系,绘制ROC曲线分析P-gp、GSTπ、TOPOⅡα单一及联合检测对TNBC患者NAC pCR的预测价值.结果 NAC后,cCR者47例(34.81%),cPR者72例(53.33%),SD者12例(8.90%),PD者4例(2.96%),总有效率88.14%;pCR者21例(15.55%).经单因素分析,P-gp、GSTπ阳性表达pCR率低于P-gp、GSTπ阴性表达pCR率,TOPOⅡα阳性表达pCR率则高于阴性性表达pCR率,差异均有统计学意义(P<0.05).P-gp、GSTπ、TOPOⅡα表达与pCR具有显著相关性[OR(95%CI)分别为1.446(1.127~1.858)、1.640(1.304~2.063)、1.548(1.227~1.984),P<0.05].P-gp、GSTπ、TOPOⅡα联合检测对NAC pCR灵敏度、特异度分别为90.73%、86.73%,AUC(95%CI)为0.813(0.743~0.908),均高于上述指标单一检测(P<0.05).结论 P-gp、GSTπ和TOPOⅡα表达与TNBC患者NAC pCR有一定关联,且通过联合上述指标检测NAC pCR有着较高预测价值,有利于帮助临床医生为TNBC患者进一步制定更合适的治疗策略.
Predictive value of P-gp,GSTπ combined with TOPO Ⅱα detection for pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
Objective To analyze the predictive value of P-glycoprotein (P-gp),glutathione transferase(GSTπ)combined with topoisomerase Ⅱα(TOPO Ⅱα)assay for pathological complete remission (pCR) of neoadjuvant chemotherapy (NAC) in patients with triple negative breast cancer (TNBC). Meth-ods This study is a retrospective,single-center,double-blind trial. A total of 135 TNBC patients,all fe-male,were selected from the First Affiliated Hospital of Zhengzhou University from March 2020 to October 2022 and screened according to the inclusion and exclusion criteria. SP immunohistochemistry was used to de-tect P-gp,GSTπ,and TOPO Ⅱα to analyze the efficacy of NAC in TNBC patients,and single and multifacto-rial analyses were performed to analyze the relationship between the expression status of P-gp ,GSTπ,and TOPO Ⅱα and NAC pCR. ROC curves were plotted to analyze the predictive value of P-gp ,GSTπ,and TOPO Ⅱα single and combined assays on NAC pCR in TNBC patients. Results After NAC,47 cases (34.81%)achieved complete clinical response(cCR),72 cases(53.33%)achieved partial cPR,12 cases (8.90%)had SD,and 4 cases(2.96%)had PD. The total effective rate was 88.14%. With 21 cases(15.55%)achieving pCR. Following NAC,21 cases(15.55%)achieved pCR,in univariate analysis,the pCR rate was lower for positive expression of P-gp and GSTπcompared to expression,while the pCR rate of positive expres-sion of TOPO Ⅱα compared to negative expression,with statistically significant differences(P<0.05). P-gp, GSTπ,and TOPO Ⅱα expression were significantly associated with pCR[OR(95%CI)1.446(1.127~1.858), 1.640(1.304~2.063),and 1.548(1.227~1.984),respectively,(P<0.05)]. The sensitivity and specificity of com-bined detection of P-gp,GSTπ,and TOPO Ⅱα for NAC pCR were 90.73%and 86.73%,respectively,with an AUC(95%CI )of 0.813(0.743-0.908);all of which were higher than single detection of theseindicators(P<0.05). Conclusion The expression of P-gp,GSTπand TOPO Ⅱα was found to be correlated with NAC pCR in TNBC patients. Combining the above indicators for the detection of NAC pCR has a high predictive value. This is beneficial in helping clinicians develop more appropriate treatment strategies for TNBC patients.

P-glycoproteinTopoisomerase ⅡαGlutathione transferaseTriple-negative breast cancerNeoadjuvant chemotherapy

吕宁、王芳、陈卓

展开 >

郑州大学第一附属医院乳腺外科,河南,郑州450000

P-糖蛋白 拓扑异构酶Ⅱα 谷胱甘肽转移酶 三阴性乳腺癌 新辅助化疗

河南省医学科技攻关计划

201702016

2024

分子诊断与治疗杂志
中山大学

分子诊断与治疗杂志

CSTPCD
影响因子:0.65
ISSN:1674-6929
年,卷(期):2024.16(3)
  • 14